Drug Screening Market Size to Hit $11.6 Billion, Globally, by 2026 with 16.8% CAGR -Study by MarketsandMarkets™ | Abbott Laboratories (US), Thermo Fisher Scientific (US), Quest Diagnostics (US)

According to the new market research report "Drug Screening Market by Product (Consumables, Urine Testing Devices, Analytical, Breathalyzer, Chromatography, Immunoassay) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 11.6 billion by 2026, from USD 5.3 billion in 2021, at a CAGR of 16.8% during the forecast period.

Browse in-depth TOC on "Drug Screening Market"
228 - Tables
36 - Figures
223 - Pages

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Key Market Players

The drug screening market is highly competitive with the presence of several small and big players. Some of the players offering products for drug screening market include Abbott Laboratories (US), Thermo Fisher Scientific (US), Quest Diagnostics (US), Alfa Scientific Designs (US), Roche (Switzerland), OraSure Technologies (US), MPD Inc. (US), and Shimadzu (Japan).

Global Drug Screening Market Dynamics

DRIVER: Growing drug and alcohol consumption
Drug abuse and alcohol consumption are increasing worldwide. According to the World Drug Report 2021, in 2019, an estimated 275 million people worldwide aged 15-64, or 1 in every 18 people in that age group, have used drugs at least once in the previous year (range: 175 million to 374 million. In 2019, 36.3 million people, or almost 13% of the global population, were estimated to be suffering from drug use disorders. In the same year, drug use killed almost half a million people, while drug use disorders resulted in 18 million years of healthy life lost, mainly due to opioids Alcohol consumption has shown similar increases, with consequences witnessed in the rising incidence of impaired driving. The rising consumption of illicit drugs & alcohol will further increase the development of drug screening products & services on the road, thereby driving the overall market growth.

Gather more insights about the market drivers, restrains and growth of the @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

RESTRAINT: prohibition on workplace drug testing in some countries

Some countries such as Canada, Colombia, Argentina, Chile, and South Africa, consider drug & alcohol testing at the workplace to be a violation of employee privacy. For instance, pre-employment drug testing is only performed in France when physicians recommend the test. In Poland and the Czech Republic, drug & alcohol tests in the workplace are prohibited. In Canada, the Eastern Canadian case laws permit drug & alcohol testing only when workplace operations are inherently dangerous or where drug and alcohol testing is limited to a few special cases. Such prohibitions in various countries may hinder the adoption of drug & alcohol testing in these markets, thus restraining overall market growth to a certain extent.

OPPORTUNITY: Emerging economies

Fingerprint-based drug testing is a relatively new concept that has gained significance due to the COVID-19 pandemic. The coronavirus has made it difficult to execute drug testing in hospitals, labs, and other facilities due to the risk of transmitting the infection. Although fingerprint-based drug screening can help limit the spread of COVID, it is noninvasive, portable, less time-consuming, hygienic, enables social distancing, is user-friendly, and requires no specific preparation for sample collection and handling. This test is very easy to implement whenever and wherever required, thus offering flexible and effective workplace drug testing. The test analyzes small traces of sweat in the fingerprint to detect drug and drug metabolites.

This test is used in workplaces, criminal justice, law enforcement, and drug rehabilitation programs. The test analyzes small traces of sweat in the fingerprint to detect drug and drug metabolites. If this test is widely adopted, it is expected to replace urine, hair, and blood-based drug tests. This is a significant opportunity for the market players to capitalize on in the drug screening market.

North America to dominate the drug screening market.

North America is expected to dominate the market with a share of 48.2%, followed by Europe. The large share of this geographical segment is attributed to factors such as growing consumption of illicit drugs, the availability of government funding to curb drug abuse, laws supporting drug screening, the growing burden of accidents due to alcohol impairment, and the presence of key players in the region are driving the growth of the drug screening market in this region.

Recent Developments

• Quest Diagnostics and Select Health of South Carolina entered into an agreement to expand Select Health's laboratory network for its Medicaid and Medicare-Medicaid dual-eligible enrollees and to enhance access to diagnostics information services for members.

• LabCorp Entered into a multi-year agreement with Infirmary Health (US) to offer laboratory testing services in the eastern Gulf Coast.

• Psychemedics introduced a vaping panel test that detects the ingestion of marijuana, and nicotine drugs by all methods, including electronic cigarettes or smoking

• Thermo Fisher Scientific introduced CEDIA Mitragynine (Kratom) Assay for the detection of Kratom for criminal justice and forensic use only

• Omega Laboratories introduced the Omega Hair 17-panel drug test capable of detecting 45 different substances, including eight commonly abused variants of benzodiazepines

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=162987773&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/drug-alcohol-screening-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/drug-alcohol-screening.asp

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.